Categories

Merck provides new information on Treatment for Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

KEYTRUDA® (pembrolizumab) Injection 100 mg is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. 1 month. Consider administration of other systemic immunosuppressants in […]

Read More No Comments

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

Clinical utility study in stage I-IV colorectal cancer (CRC) evaluates how adjuvant treatment decisions are impacted by using the Signatera™ MRD test Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a milestone with over 100 sites initiated and 1,000 patients enrolled across the U.S. in its BESPOKE CRC study, a prospective, […]

Read More No Comments

Merck announces new FDA approval for KEYTRUDA®

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.    •  PD-L1 diagnostic testing is required prior to initiating treatment with […]

Read More No Comments

Oncopeptides announces that PEPAXTO® is now included in the NCCN Clinical Practice Guidelines.

Melphalan Flufenamide (PEPAXTO®) is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 6.2021 – April 12, 2021 Category 2A1 Definitions for National Comprehensive Cancer Network® (NCCN®) Categories:   Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.   For more […]

Read More No Comments

FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy

U.S. Food and Drug Administration cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss (alopecia) during chemotherapy. This is the first cooling cap cleared by the agency for use in cancer patients with solid tumors.

Read More No Comments

Doctors’ Notes: Younger Patients Face Unique Challenges Post-Cancer

Patients between 15 and 39 must deal with psychosocial effects of cancer and recovery.

Read More No Comments

Helping Children When a Family Member Has Cancer

This series of guides offers extensive information on helping children understand and deal with cancer in another family member.

Read More No Comments

PBMs Costing Medicare & Beneficiaries More for Drugs

WASHINGTON, D.C. – February 1, 2017 – A new White Paper by the law firm of Frier Levitt, LLC examines the ongoing practice by pharmacy Benefit Managers (PBMs) to increase corporate profits through murky “direct and indirect remuneration” fees (commonly known as “DIR Fees”) charged to community oncology practices, as well as retail and specialty […]

Read More No Comments

Cobas EGFR Mutation Test v2

On June 1, 2016, the U. S. Food and Drug Administration approved cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.) using plasma specimens as a companion diagnostic test for the detection of exon 19 deletions or exon 21 (L858R) substitution mutations in the epidermal growth factor recptor (EGFR) gene to identify patients with metastatic […]

Read More No Comments

Landmark Study Takes In-Depth Look at Cost Drivers of Cancer Care

New Milliman Study Commissioned by Community Oncology Alliance Finds Costs for Treating Patients With Cancer Increased at Essentially Same Rate as Other Health Care Spending

Read More No Comments